Preclinical Pharmacokinetic Evaluation of Cardiovascular Drugs

It is essential for cardiovascular drugs to have an ideal pharmacokinetic profile in order to achieve their intended therapeutic effects. Ace Therapeutics offers a full range of pharmacokinetic study solutions for cardiovascular drugs to meet the needs of preclinical studies.

Pharmacokinetic Study for Cardiovascular Drugs

Generally, cardiovascular drugs must enter the bloodstream and remain there for an appropriate period to exert their therapeutic effects, which places high demands on their pharmacokinetic properties. Therefore, preclinical pharmacokinetic studies are essential to understand the concentration of cardiovascular drugs in various parts of the body over time and to elucidate the quantitative changes of these drugs within the body. This information provides a scientific basis for developing subsequent drug dosage forms and delivery systems.

Fig. 1 3D cell culture models for drug pharmacokinetics. (Wang H, et al., 2021)

Ace Therapeutics can provide clients with in vitropharmacokinetic properties and in vivo pharmacokinetic studies in the early stages of cardiovascular drug development.

Ace Therapeutics is a contract research outsourcing service provider specializing in cardiovascular drug research. With a specialized pharmacokinetic research technology platform, we are able to provide preclinical pharmacokinetic services for cardiovascular drugs according to our clients' needs. If you are interested in our services, please don't hesitate to contact us.

1. Wang, H.; et al. 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. Clin Transl Sci. 2021, 14(5):1659-1680.